NovoCure Management
Management criteria checks 3/4
NovoCure's CEO is Ashley Cordova, appointed in Jan 2025, has a tenure of less than a year. total yearly compensation is $6.32M, comprised of 8.3% salary and 91.7% bonuses, including company stock and options. directly owns 0.11% of the company’s shares, worth $2.52M. The average tenure of the management team and the board of directors is 1.5 years and 7.3 years respectively.
Key information
Ashley Cordova
Chief executive officer
US$6.3m
Total compensation
| CEO salary percentage | 8.3% |
| CEO tenure | less than a year |
| CEO ownership | 0.1% |
| Management average tenure | 1.5yrs |
| Board average tenure | 7.3yrs |
Recent management updates
Recent updates
Some Confidence Is Lacking In NovoCure Limited (NASDAQ:NVCR) As Shares Slide 25%
Mar 01
NovoCure's Expansion Strategy Struggles To Translate Approvals Into Growth
Feb 28Does NovoCure (NASDAQ:NVCR) Have A Healthy Balance Sheet?
Feb 12NovoCure Limited (NASDAQ:NVCR) Looks Just Right With A 84% Price Jump
Dec 03Novocure Moves Pancreatic Cancer Treatment Forward With A 'First' Using TTFields
Dec 02Analyst Estimates: Here's What Brokers Think Of NovoCure Limited (NASDAQ:NVCR) After Its Third-Quarter Report
Nov 01Is NovoCure (NASDAQ:NVCR) A Risky Investment?
Oct 17NovoCure: There Is Still More Upside
Oct 16NovoCure's Stock Stagnates Amid Lack Of Progress Beyond GBM
Oct 09Investors Appear Satisfied With NovoCure Limited's (NASDAQ:NVCR) Prospects
Sep 12NovoCure Limited: A Post Q2 Analysis
Jul 26NovoCure Limited Q1 Earnings: Core Business Accelerating
May 03NovoCure (NASDAQ:NVCR) Has Debt But No Earnings; Should You Worry?
Apr 08NovoCure: Sell The METIS-Inspired Rally
Mar 28Some Shareholders Feeling Restless Over NovoCure Limited's (NASDAQ:NVCR) P/S Ratio
Mar 03NovoCure: Stay Cautious Amid Positive Signs
Jan 19Does NovoCure (NASDAQ:NVCR) Have A Healthy Balance Sheet?
Nov 16Is NovoCure (NASDAQ:NVCR) Weighed On By Its Debt Load?
Aug 13Is NovoCure (NASDAQ:NVCR) A Risky Investment?
May 15A Look At The Intrinsic Value Of NovoCure Limited (NASDAQ:NVCR)
Apr 24Why NovoCure Limited (NASDAQ:NVCR) Could Be Worth Watching
Feb 10CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Dec 31 2024 | n/a | n/a | -US$169m |
| Sep 30 2024 | n/a | n/a | -US$150m |
| Jun 30 2024 | n/a | n/a | -US$169m |
| Mar 31 2024 | n/a | n/a | -US$193m |
| Dec 31 2023 | US$6m | US$525k | -US$207m |
| Sep 30 2023 | n/a | n/a | -US$197m |
| Jun 30 2023 | n/a | n/a | -US$174m |
| Mar 31 2023 | n/a | n/a | -US$141m |
| Dec 31 2022 | US$7m | US$508k | -US$93m |
| Sep 30 2022 | n/a | n/a | -US$82m |
| Jun 30 2022 | n/a | n/a | -US$68m |
| Mar 31 2022 | n/a | n/a | -US$59m |
| Dec 31 2021 | US$5m | US$478k | -US$58m |
| Sep 30 2021 | n/a | n/a | -US$27m |
| Jun 30 2021 | n/a | n/a | -US$5m |
| Mar 31 2021 | n/a | n/a | US$12m |
| Dec 31 2020 | US$3m | US$367k | US$20m |
Compensation vs Market: Ashley's total compensation ($USD6.32M) is about average for companies of similar size in the US market ($USD5.43M).
Compensation vs Earnings: Ashley's compensation has been consistent with company performance over the past year.
CEO
Ashley Cordova (45 yo)
less than a year
Tenure
US$6,317,066
Compensation
Ms. Ashley Cordova serves as Chief Executive Officer of NovoCure Limited since January 1, 2025 and had been its Chief Financial Officer since September 01, 2020 until January 1, 2025. From October 2018 to...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Executive Chairman | 21.2yrs | US$1.43m | 0.50% $ 11.1m | |
| Chief Executive Officer | less than a year | US$6.32m | 0.11% $ 2.5m | |
| General Counsel | 2.9yrs | US$4.86m | 0.051% $ 1.1m | |
| Executive VP & President of Novocure Oncology | 4.5yrs | US$5.04m | 0.059% $ 1.3m | |
| Chief Financial Officer | less than a year | no data | 0.0054% $ 118.4k | |
| Chief Operating Officer | less than a year | no data | 0.077% $ 1.7m | |
| VP of Investor Relations | no data | no data | no data | |
| Chief Human Resources Officer | 1.5yrs | no data | 0.033% $ 720.8k | |
| Chief Innovation Officer | 2.2yrs | no data | 0.098% $ 2.2m | |
| Chief Medical Officer | 1.2yrs | no data | 0.015% $ 321.9k |
1.5yrs
Average Tenure
50.5yo
Average Age
Experienced Management: NVCR's management team is not considered experienced ( 1.5 years average tenure), which suggests a new team.
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Executive Chairman | 21.2yrs | US$1.43m | 0.50% $ 11.1m | |
| Independent Director | 6.7yrs | US$446.09k | 0.0023% $ 50.9k | |
| Independent Director | 6.8yrs | US$426.09k | 0.0083% $ 183.4k | |
| Director | 13.2yrs | US$1.52m | 0.014% $ 313.8k | |
| Independent Director | 4.1yrs | US$448.53k | 0.0036% $ 78.7k | |
| Independent Director | 13.4yrs | US$435.53k | 0.072% $ 1.6m | |
| Lead Independent Director | 19.2yrs | US$475.53k | 0.15% $ 3.2m | |
| Independent Director | 7.8yrs | US$446.09k | 0.014% $ 313.3k | |
| Independent Director | 2yrs | US$696.94k | 0% $ 0 | |
| Independent Director | 2.1yrs | US$697.26k | 0% $ 0 |
7.3yrs
Average Tenure
62yo
Average Age
Experienced Board: NVCR's board of directors are considered experienced (7.3 years average tenure).
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/03/14 23:33 |
| End of Day Share Price | 2025/03/14 00:00 |
| Earnings | 2024/12/31 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
NovoCure Limited is covered by 13 analysts. 7 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Gregory Gilbert | Deutsche Bank |
| Vijay Kumar | Evercore ISI |
| Emily Bodnar | H.C. Wainwright & Co. |